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Diabetes is a systemic disease that causes a number of metabolic and physiologic abnormalities. One of the major microvascular
complications of diabetes is diabetic retinopathy (DR), a leading cause of blindness in people over age 50. The mechanisms
underlying the development of DR are not fully understood; however, extensive studies have recently implicated chronic, low-
gradeinﬂammation inthepathophysiologyofDR.Duringinﬂammation leukocytes undergo sequential adhesiveinteractionswith
endothelialcellstomigrateintotheinﬂamedtissues,aprocessknownasthe“leukocyterecruitmentcascade”whichisorchestrated
by precise adhesion molecule expression on the cell surface of leukocytes and the endothelium. This paper summarizes the recent
clinical and preclinical works on the roles of leukocyte adhesion molecules in DR.
1.Introduction
Inﬂammationisanonspeciﬁc,defensiveresponseofthebody
to tissue injury in which leukocytes are recruited to in-
ﬂamed tissues. In acute inﬂammation, leukocytes clear away
invading agents and degrade necrotized tissue components,
generally contributing to tissue repair. However, if inﬂam-
mation persists chronically, leukocytes can damage tissues by
prolonged secretion of chemical mediators and toxic oxygen
radicals. There is an accumulating body of evidence showing
that leukocytes play a signiﬁcant role in the pathogenesis
of a number of vision-threatening retinal diseases, such as
glaucoma, age-related macular degeneration, and diabetic
retinopathy (DR) [1]. This paper will present important
ﬁndings from the growing amount of research on inﬂamma-
tion speciﬁcally in relation to DR.
DR is one of the main microvascular complications of
diabetes and one of the most common causes of blindness
in people over age 50. Recent studies have elucidated that
chronic, low-grade inﬂammation underlies much of the vas-
cular complications of DR [2, 3]. Microscopic inﬂammatory
responses, such as vessel dilation, vascular leakage, and leu-
kocyte recruitment, occur in the diabetic retina and are im-
plicated in the development of DR [4].
For instance, leukocyte adhesion molecules are upregu-
lated in the vessels of the diabetic retina and choroid, and
consequently inﬂammatory cells accumulate in the chori-
oretinal tissues [5]. Indeed, extensive accumulation of poly-
morphonuclear leukocytes has been observed in the lumen
of microaneurysms, a cause of retinal vascular leakage, in
human type 1 diabetic subjects [6, 7]. Correlations between
elevated numbers of accumulated leukocytes and capillary
damagehavebeenshowninpostmortemDRpatients[6]and
in spontaneously diabetic monkeys [8]. Preclinical studies
using animal models of early DR have also revealed that
leukocytes adhering to the endothelium damage endothelial
cells and increase the vascular permeability of retinal vessels
[9, 10]. Leukocytes have also been shown to be present
in ﬁbrovascular membranes, a characteristic feature of the
pathologic changes associated with proliferative diabetic
retinopathy (PDR) [11]. It has been furthermore reported
that T lymphocytes inﬁltrate the ﬁbrovascular membrane
[12] and that this inﬁltration correlates well with the se-
verity of retinopathy and poor visual prognosis [13]. Taken
together, these lines of evidence indicate that leukocytes dis-
rupt the homeostasis of the vasculature and facilitate prolif-
erative damage in DR.2 Journal of Ophthalmology
The following sections describe the leukocyte recruit-
ment cascade, which is regulated by a series of adhesion
molecules, and present the emerging ﬁndings regarding the
adhesion molecules speciﬁcally involved in DR.
2.LeukocyteRecruitment Cascade
The recruitment of leukocytes from circulating blood into
tissues is crucial for the inﬂammatory response. During the
process, a number of well-studied adhesion molecules on
the endothelium sequentially interact with their ligands ex-
pressed on the cell surface of leukocytes. The interaction
between adhesion molecules and ligands occurs in a cascade-
like fashion, guiding leukocytes from the circulation to the
extravascular space, that is, through the steps of leukocyte
rolling, ﬁrm adhesion, and transmigration (Figure 1).
The selectin family of adhesion molecules mediates the
capture and rolling steps of leukocytes along the endothelial
cells. The selectins consist of three members of C-type lec-
tins: P-, E-, and L-selectin [14]. P-selectin, stored in the
granules of endothelial cells and platelets, translocates
rapidlytothecellsurfaceinresponsetoseveralinﬂammatory
stimuli. Whereas all of the selectins bind to sialyl-Lewis X
carbohydrate ligands, such as P-selectin glycoprotein ligand-
1 (PSGL-1), interaction between P-selectin and PSGL-1 is
responsible for a major part of the leukocyte rolling in
inﬂammation [15]. E-selectin, a heavily glycosylated trans-
membrane protein, is present exclusively in endothelial cells
and is increased by stimulation of representative inﬂamma-
tory cytokines, such as tumor necrosis factor- (TNF-) α and
interleukin- (IL-) 1β [16]. These inﬂammatory cytokines
are also reported to induce the expression of P-selectin on
the endothelium [17, 18]. L-selectin is expressed on many
subclassesof leukocytes[14] and binds to endothelial ligands
containing sulfated sialyl Lewis X [19].
After the selectins have initiated leukocyte rolling along
the surface of the endothelium, a diﬀerent set of adhesion
molecules comes into play to reduce the leukocyte-rolling
velocity and allow the leukocytes to ﬁrmly adhere to the
endothelial surface. This ﬁrm adhesion step is largely me-
diated by molecules of the immunoglobulin superfamily,
such as intercellular adhesion molecule- (ICAM-) 1 and
vascular cell adhesion molecule- (VCAM-) 1, expressed on
endothelialcellsandbythoseoftheintegrinfamilyexpressed
constitutively on leukocytes as well as on many other types of
cells. The principal integrins that bind to endothelial ICAM-
1 are LFA-1 (CD11a/CD18) and Mac-1 (CD11b/CD18),
while VLA-4 (CD49d/CD29) is the integrin that binds to
endothelial VCAM-1 [20]. Recent studies have revealed that
the binding of selectins to PSGL-1 increase the aﬃnity of
LFA1 to ICAM-1, indicating that rolling step facilitates the
next events, leukocyte adhesion to the endothelial surface
[21].
Upon achievement of stable adhesion to the endothe-
lial surface, the leukocytes extravasate between endothelial
cells along the intercellular junctions. Platelet endothelial
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Figure 1: Leukocyte recruitment to the vessel wall.
cell adhesion molecule- (PECAM-)1 is an immunoglobu-
lin superfamily member expressed at endothelial cell-cell
junctions that mediates this leukocyte transmigration, par-
ticularly that of monocytes and neutrophils. In addition,
vascular adhesion protein- (VAP-) 1, a 170kDa homod-
imeric sialylated glycoprotein, is an endothelial adhesion
molecule regulating the transmigration step of lymphocytes,
monocytes, and polymorphonuclear leukocytes. VAP-1 was
originally discovered in inﬂamed synovial vessels [22], and;
thereafter, it was revealed that it is also expressed on the
vascular endothelial cells in tissues such as skin, brain, lung,
liver,andheart[23–26].Inoculartissues,VAP-1wasdetected
on the endothelial cells of retinal and choroidal vessels [27–
29].
3.LeukocyteAdhesion Molecules in
DiabeticRetinopathy
Clinically, DR is divided into two stages based on the
proliferative status of the retinal vasculature: the non-
proliferativestage(NPDR)andtheproliferativestage(PDR).
InNPDR,theearlystageofDR,thedevelopmentofretinopa-
thy begins with vascular lesions that involve pericyte loss,
basement membrane thickening, capillary microaneurysms,
andobliterationofcapillaries[11].Theobliteratedcapillaries
reducetheamountofretinalperfusionand,therefore,leadto
ischemic changes in the diabetic retina. This ischemia causes
neovascularization in the retina and/or the optic disk. PDR,
the later stage of DR, is characterized by retinal neovascu-
larization associated with the formation of a ﬁbrovascular
membrane at the vitreoretinal interface. Tractional change
against the ﬁbrovascular membrane leads to further severe
complications, such as vitreous hemorrhage and tractional
and/or rhegmatogenous retinal detachments. Clinical and
preclinical studies have provided evidence that leukocyte
adhesion molecules play a signiﬁcant role during both stages
of DR.
4.Selectins
The data regarding the role of the selectin family speciﬁcally
in the retinal vessels in DR turns out to be rather intriguing,
especially in light of the selectin family’s generally known
responsibility for leukocyte rolling as described above.
Reports show, for instance, that P-selectin is upregulated inJournal of Ophthalmology 3
thechoroidalvesselsofdiabeticpatients,butitisnotupregu-
lated in their retinal vessels [5]. Moreover, E-selectin has not
been detected in the chorioretinal tissues of either diabetic or
nondiabetic patients [5]. On the leukocyte side, a signiﬁcant
decrease in the amount of surface L-selectin expression has
been observed in patients with diabetic microangiopathy in
comparisonwithdiabeticpatientswithoutmicroangiopathic
complications and healthy controls [30].
The reason for this pattern of diminished selectin ex-
pression on the leukocytes and endothelial cells in DR
might be due to the speciﬁc nature of the inﬂammation in
DR, that is, in its chronic, low-grade nature. It is known,
for instance, that selectins are removed from the cell surface
of leukocytes and endothelia through proteolytic shedding
during inﬂammation [31], and this seems to be what is
occurring under the longstanding and subclinical inﬂam-
matory conditions of DR. Indeed, elevated serum levels of
soluble adhesion molecules have been reported in patients
with DR; the serum level of soluble E-selectin, for example,
is reportedly increased in patients with diabetes [32, 33]
and correlates with the progression of DR [34, 35]. It has
also been demonstrated that patients with PDR show higher
serum levels of soluble P-selectin [36].
As for the mechanisms, it has been reported that a
disintegrin and metalloproteinase (ADAM) 8, one of the
major ectodomain shedding proteinases, is upregulated dur-
ing pathological neovascularization, and its overexpression
facilitates the shedding of E-selectin [37]. Similarly, during
inﬂammation, L-selectin is shed by ADAM17, which is
upregulated in response to inﬂammatory stimulation [38,
39].
In the vitreous, the level of soluble E-selectin was con-
siderably higher in subjects with PDR [40]. Furthermore,
vitreous levels of soluble E-selectin in eyes with PDR
complicated by traction retinal detachment were signiﬁ-
cantly increased in comparison with the eyes with vitreous
hemorrhage alone [41]. Interestingly, it has been shown that
soluble E-selectin stimulates retinal capillary endothelial cell
migration [42] and promotes angiogenesis through a sialyl-
Lewis-X-dependent mechanism [43].
Accordingly, these various lines of evidence indicate that
the shedding of selectins is enhanced on the endothelium
during the progression of diabetes and that the soluble form
of selectin proteins has the potential to be a clinically useful
biomarkeroftheseverityofDR;E-selectin,inparticular,may
also serve as a proangiogenic factor.
5.ICAM-1
While the selectin expression on leukocytes and endothelial
cells appears low in DR, other molecules may be compen-
sating for the adhesion gaps. Several studies, for instance,
suggest that ICAM-1 and its binding partners are operative
in DR and may serve as potential targets for therapeu-
tic interventions. Indeed, ICAM-1 is found to be highly
expressed in the blood vessels of the retina, choroid and ﬁ-
brovascular membrane in patients with diabetes [5, 44],
and its expression correlates with the number of migrated
neutrophils in the retina and choroid of these patients
[5], indicating that elevated ICAM-1 facilitates leukocyte
recruitment and the vascular complications in DR. In accord
with these clinical observations, ICAM-1 is increased in the
retinal vessels in an animal model of DR, and blockade of
ICAM-1 attenuated leukostasis, endothelial cell death, and
vascular leakage in the retinal vessels of the diabetic animals
[10].
Not only ICAM-1 but also LFA-1 (CD11a/CD18) and
Mac-1 (CD11b/CD18) ligands for ICAM-1 are upregulated
in patients with diabetes. The β-integrin subunit CD18 is
increased in patients with DR [45], and likewise signiﬁcant
increases in α-integrin subunits CD11a [46] and CD11b
[30] are found in these patients. Consequently, these data
indicate that ICAM-1 and its ligands are important and
interruption of either component of the integrin-ICAM-1
interaction may be beneﬁcial in preventing the deterioration
of DR.However, it wasalsoreported thatthe eﬀectofICAM-
1 depletion was limited to prevent angiogenesis in oxygen-
induced retinopathy model [47]. Further investigation is still
requiredtoelucidatetheroleofintegrin-ICAM-1interaction
in DR.
6. VCAM-1
Similar to ICAM-1, a role for endothelial VCAM-1 in DR is
also emerging, although there has not been as much research
conducted on VCAM-1 as with ICAM-1. Before its potential
role in DR was examined, it ﬁrst came to light that VCAM-
1 had been involved in the macrovascular complications
of diabetes [48]; however, it has since been revealed that
the interaction of VCAM-1 with its ligand, integrin VLA-
4, is important in the development of DR. For instance,
it has been demonstrated in an animal model of DR that
hyperglycemiaupregulatesVCAM-1expressionintheretinal
vessels[49].Also,inananimalmodelofearlyDR,ithasbeen
foundthatVLA-4-mediatedleukocyteadhesiontotheretinal
vessels is signiﬁcantly increased, and blockade of VLA-4
attenuates vascular leakage and production of inﬂammatory
cytokines [50].
In addition, increased serum levels of soluble VCAM-1
have been found in type 2 diabetic patients with microvas-
cular complications, similar to E-selectin [32], and levels of
soluble VCAM-1 are elevated in the vitreous of DR patients
as well [40, 41]. Notably, it has been shown that soluble
VCAM-1 acts on endothelial cells as an angiogenic factor
through a VLA-4-dependent mechanism, in common with
E-selectin [42, 43], suggesting that blockade of both soluble
adhesion molecules, soluble forms of E-selectin and VCAM-
1, could have a beneﬁcial eﬀect on DR.
7. VAP-1
Along with ICAM-1, VAP-1 seems also to be a key player
in the inﬂammation associated with DR, as demonstrated
through several lines of evidence. Blockade of VAP-1, for
example, signiﬁcantly reduces the transmigration and/or
capillary entrapment of leukocytes in the retina in an4 Journal of Ophthalmology
animal model of DR [51]. Transmigrated leukocytes under
pathological conditions are thought to play an impor-
tant role in neovascularization through secretion of VEGF
[52]. Furthermore, leukocytes ﬁrmly adhering to capillary
endothelial cells induce apoptotic changes in the endothelial
cells [53]. Therefore, VAP-1 seems to be locally involved in
the pathogenesis of DR by mediating leukocyte recruitment.
In further support of this conclusion, VAP-1 also exists as
a soluble form in plasma, and much attention has recently
been paid to the elevated serum concentration of soluble
VAP-1 in patients with diabetes [54, 55]. Interestingly, be-
sides its role as an adhesion molecule, VAP-1 has also an
enzymatic function as a semicarbazide-sensitive amine oxi-
dase (SSAO), which converts aliphatic primary monoamines
to the corresponding aldehydes with the release of hydrogen
peroxide and ammonia [56]. Metabolites generated by VAP-
1/SSAO, for example, hydrogen peroxide and methylglyoxal
from aminoacetone are known to be involved in cellular
oxidative stress and advanced glycation end-product for-
mation, both of which are crucial for the pathogenesis of
diabetic retinopathy [57, 58]. Therefore, it seems likely that
soluble VAP-1 in the serum and vitreous may promote vas-
cular complications in DR. In fact, patients with DR display
signiﬁcantly higher plasma VAP-1/SSAO activities compared
to patients without DR [55]. Further investigation using
human ocular samples may aid in a better understanding of
the role of VAP-1 in DR.
8. Conclusions
T h ep a t h o g e n e s i so fD Ri sn o te n t i r e l yk n o w n .H o w e v e r ,
based on the preceding discussion, growing evidence sup-
ports a role for leukocytes and their adhesion molecules in
the development of DR. In addition, soluble adhesion mol-
ecules may contribute to DR by acting as angiogenic fac-
tors or enzymes. Speciﬁc inhibition of leukocyte adhesion
moleculescouldbeoftherapeuticvaluefordiabeticpatients.
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